AmplifyBio Secures $200M to Propel Breakthroughs in Translational Science and Next-Generation Therapies

AmplifyBio is thrilled to announce a major milestone in its journey to revolutionize healthcare with the successful raise of $200 million in funding. This extraordinary achievement is a testament to the company’s relentless pursuit of innovative solutions in translational science, cell and gene therapies, and next-generation medicines aimed at transforming lives globally. By combining the strength, knowledge, and experience of its esteemed partners with the expertise of its cross-integrated teams, AmplifyBio continues to push the boundaries of medical research and development. The newly raised capital will be strategically invested to enhance the company’s state-of-the-art infrastructure, including its fully functional GLP laboratory that spans 200,000 square feet—a facility equipped with a comprehensive suite of pre-clinical models and support services essential for robust drug development. With this funding, AmplifyBio plans to accelerate its translational research efforts, expand pre-clinical testing capabilities, and pioneer innovative therapeutic solutions that address complex medical challenges. Moreover, the infusion of capital will strengthen collaborations with academic institutions, biopharmaceutical partners, and other stakeholders, fostering an ecosystem where cutting-edge research translates into breakthrough treatments. As the company charts a visionary path toward expanding its therapeutic portfolio, AmplifyBio remains committed to improving the health and well-being of millions around the world. This funding round not only validates the profound impact of their scientific endeavors but also fuels their ambition to lead the next wave of innovation in medicine, ultimately paving the way for a healthier future for people everywhere.